Management Of Blood Glucose Levels Research Articles

Evaluation of Antidiabetic Activity of Abutilon crispum on Normal and Streptozotocin-induced Diabetic Albino Wistar Rats

Background Diabetes mellitus is a disorder that affects the majority of individuals in the world. Objectives The objective of the current study is to estimate the antidiabetic effect of methanol extract of Abutilon crispum entire plant, which is broadly cultivated in India’s arid and desert areas. This current investigation aims to estimate the efficacy of methanol extract of A. crispum to prevent streptozotocin-induced diabetes mellitus in Albino Wistar strain rats. Materials and Methods In the current examination, methanol extract of the whole plant of A. crispum with doses of 250 and 500 mg/kg/b.wt (body weight) is administered through the oral route to the streptozotocin-prompted diabetic animals where n = 6. We evaluated the differences in food and water intake, body weight levels, fasting glucose, and oral glucose tolerance test (OGTT). When methanol extract of A. crispum was used to evaluate the OGTT for diabetic animals, levels of glucose were found to be pointedly lower when administered with 500 mg/kg b.wt as this is compared to the control group. A. crispum had specifically declined the levels of glucose elevated in diabetic rats. A. crispum is a vital alternative source for managing blood glucose levels in diabetes mellitus that have increased during the condition and need to be further reduced by oral medications that cause hypoglycemia. Biochemical parameters were estimated as a part of the investigation. Results The results demonstrated that the dried methanol extract of A. crispum (250 mg/kg/bwt and 500 mg/kg/bwt) considerably declined those levels of blood glucose during the treatment period when compared to glibenclamide (10 mg/kg), enhanced the metabolism, improved the health of animals and enhanced the OGTT. Conclusion As a result, we can conclude that the whole plant of A. crispum methanol extract contains antidiabetic effects, as well as, hypoglycemic activities.

TNF-α inhibitors for type 1 diabetes: exploring the path to a pivotal clinical trial.

Type 1 diabetes (T1D) is an autoimmune disease characterized by the destruction of insulin-producing β-cells in the pancreas. This destruction leads to chronic hyperglycemia, necessitating lifelong insulin therapy to manage blood glucose levels. Typically diagnosed in children and young adults, T1D can, however, occur at any age. Ongoing research aims to uncover the precise mechanisms underlying T1D and to develop potential interventions. These include efforts to modulate the immune system, regenerate β-cells, and create advanced insulin delivery systems. Emerging therapies, such as closed-loop insulin pumps, stem cell-derived β-cell replacement and disease-modifying therapies (DMTs), offer hope for improving the quality of life for individuals with T1D and potentially moving towards a cure. Currently, there are no disease-modifying therapies approved for stage 3 T1D. Preserving β-cell function in stage 3 T1D is associated with better clinical outcomes, including lower HbA1c and decreased risk of hypoglycemia, neuropathy, and retinopathy. Tumor Necrosis Factor alpha (TNF-α) inhibitors have demonstrated efficacy at preserving β-cell function by measurement of C-peptide in two clinical trials in people with stage 3 T1D. However, TNF-α inhibitors have yet to be evaluated in a pivotal trial for T1D. To address the promising clinical findings of TNF-α inhibitors in T1D, Breakthrough T1D convened a panel of key opinion leaders (KOLs) in the field. The workshop aimed to outline an optimal clinical path for moving TNF-α inhibitors to a pivotal clinical trial in T1D. Here, we summarize the evidence for the beneficial use of TNF-α inhibitors in T1D and considerations for strategies collectively identified to advance TNF-α inhibitors beyond phase 2 clinical studies for stage 3 T1D.

Antihyperglycemic activity of a novel polyherbal formula (HF344), a mixture of fifteen herb extracts, for the management of type 2 diabetes: Evidence from in vitro, ex vivo, and in vivo studies

Antihyperglycemic effects of a novel polyherbal formula (HF344), comprising fifteen Thai herbal extracts, were elucidated for pharmacological mechanisms and potential for managing type 2 diabetes mellitus, by employing in vitro, ex vivo, and in vivo approaches. LC/MS analysis of HF344 extract revealed several phytoconstituents, with piperine identified as the major active compound. HF344 extract significantly enhanced insulin secretion in RINm5F cells in vitro and inhibited glucose uptake into the everted sacs of the mouse small intestine ex vivo in a concentration-dependent manner compared to the control (p < 0.05). It exhibited potent α-glucosidase inhibition in vitro, with an IC50 of 96.74 μg/mL. Moreover, HF344 extract upregulated mRNA levels of GLUT1 in L6 skeletal myoblasts, suggesting increased glucose uptake into skeletal muscle. In addition, in vivo antihyperglycemic effects were assessed in streptozotocin (STZ)-nicotinamide (NA)-induced diabetic mice. Acute oral toxicity testing confirmed the HF344 extract's safety, with an LD50 exceeding 2000 mg/kg. Oral administration of HF344 extract (500 and 1000 mg/kg) in STZ-NA-induced diabetic mice significantly reduced the area under the fasting blood glucose (FBG)-time curve (AUC) in the oral glucose tolerance test (OGTT) model and treatment for 28-day reduced the FBG levels as compared with control (p < 0.05). This was accompanied by increased serum insulin levels and improved insulin resistance. HF344 extract also demonstrated a concentration-dependent inhibitory effect on malondialdehyde (MDA) production in vitro, with an IC50 of 7.24 μg/mL. Oral treatment with HF344 extract decreased MDA production in the homogenized muscle ex vivo collected from STZ-NA-induced mice. Furthermore, pretreatment with HF344 extract effectively restored the survival of RINm5F cells from STZ-induced damage. These findings suggest that HF344 is a promising polyherbal formula for managing blood glucose levels, enhancing insulin production, and providing antioxidant benefits in T2DM. Further research is required to evaluate the clinical efficacy and safety profiles of HF344.

Body weight training versus series 7 diabetes dance: their influence on glucose levels in patients with type 2 diabetes mellitus

Managing blood glucose levels is critical for preventing complications associated with type 2 diabetes mellitus (T2DM). Physical activity has been shown to be an effective strategy for glucose control, with various forms of exercise yielding different results. This research aims to explore the effects of body weight training and series 7 diabetes dance on reducing blood glucose levels in patients with T2DM, and to compare the efficacy of these two interventions in achieving glucose control. The type of research was a quasi-experiment with a two groups pre-test post-test design. The series 7 diabetes dance group performed the exercise 4 times a week (duration: 170 minutes 8 seconds/week), while the body weight training group performed exercise 3 times a week (8 movements, number of repetitions close to failure, circuit system, 3 sets per training session). Both groups were doing an exercise program for three months. The research sample was for about 16 patients of type 2 diabetes mellitus (8 people per group, devided randomly), taken by using non probability sampling technique, purposive sampling type (effect size 1.6, significant level (α) 0.05 and Power 0.8). The data analysis used the paired sample t test and the independent t test with a significance level of α = 0.05.The results showed that 1) there is no significant effect of series 7 diabetes dance towards the decreasing the level of blood sugar of the patients with type 2 diabetes mellitus), 2) there is a significant effect of body weight training towards the decreasing level of blood glucose of the patients with type 2 diabetes mellitus, 3) dody weight training is more effective in decreasing the level of blood glucose of patients with type 2 diabetes mellitus compared to series 7 diabetes dance. Future research must be carried out as a true experiment with a larger number of samples and with the HbA1c research instrument.

Excess glucose alone induces hepatocyte damage due to oxidative stress and endoplasmic reticulum stress

Type 2 diabetes mellitus (DM) is a significant risk factor for metabolic dysfunction-associated steatotic liver disease (MASLD) and hepatocellular carcinoma (HCC). With the increasing prevalence of type 2 DM and MASLD due to lifestyle changes, understanding their impact on liver health is crucial. However, the hepatocellular damage caused by glucose alone is unknown. This study investigates the effect of excess glucose on hepatocytes, focusing on oxidative stress, endoplasmic reticulum stress (ER stress), apoptosis, autophagy, and cell proliferation. We treated an immortalized-human hepatocyte cell line with excess glucose and analyzed. Excess glucose induced oxidative stress and ER stress in a time- and concentration-dependent manner, leading to apoptosis. Oxidative stress and ER stress were independently induced by excess glucose. Proteasome inhibitors and palmitic acid exacerbated glucose-induced stress, leading to the formation of Mallory-Denk body-like inclusion bodies. Despite these stresses, autophagic flux was not altered. Excess glucose also caused DNA damage but did not affect cell proliferation. This suggests that glucose itself can contribute to the progression of metabolic dysfunction-associated steatohepatitis (MASH) and carcinogenesis of HCC in patients with type 2 DM. Managing blood glucose levels is crucial to prevent hepatocyte damage and associated complications.

An antifibrotic compound that ameliorates hyperglycaemia and fat accumulation in cell and HFD mouse models.

Appropriate management of blood glucose levels and the prevention of complications are important in the treatment of diabetes. We have previously reported on a compound named HPH-15 that is not only antifibrotic but also AMP-activated protein kinase (AMPK)-activating. In this study, we evaluated whether HPH-15 is useful as a therapeutic medication for diabetes. We examined the effects of HPH-15 on AMPK activation, glucose uptake, fat accumulation and lactic acid production in L6-GLUT4, HepG2 and 3T3-L1 cells, as a model of muscle, liver and fat tissue, respectively. Additionally, we investigated the glucose-lowering, fat-accumulation-suppressing, antifibrotic and AMPK-activating effect of HPH-15 in mice fed a high-fat diet (HFD). HPH-15 at a concentration of 10 µmol/l increased AMPK activation, glucose uptake and membrane translocation of GLUT4 in each cell model to the same extent as metformin at 2 mmol/l. The production of lactic acid (which causes lactic acidosis) in HPH-15-treated cells was equal to or less than that observed in metformin-treated cells. In HFD-fed mice, HPH-15 lowered blood glucose from 11.1±0.3 mmol/l to 8.2±0.4 mmol/l (10 mg/kg) and 7.9±0.4 mmol/l (100 mg/kg) and improved insulin resistance. The HPH-15 (10 mg/kg) group showed the same level of AMPK activation as the metformin (300 mg/kg) group in all organs. The HPH-15-treated HFD-fed mice also showed suppression of fat accumulation and fibrosis in the liver and fat tissue; these effects were more significant than those obtained with metformin. Mice treated with high doses of HPH-15 also exhibited a 44% reduction in subcutaneous fat. HPH-15 activated AMPK at lower concentrations than metformin in vitro and in vivo and improved blood glucose levels and insulin resistance in vivo. In addition, HPH-15 was more effective than metformin at ameliorating fatty liver and adipocyte hypertrophy in HFD-fed mice. HPH-15 could be effective in preventing fatty liver, a common complication in diabetic individuals. Additionally, in contrast to metformin, high doses of HPH-15 reduced subcutaneous fat in HFD-fed mice. Presumably, HPH-15 has a stronger inhibitory effect on fat accumulation and fibrosis than metformin, accounting for the reduction of subcutaneous fat. Therefore, HPH-15 is potentially a glucose-lowering medication that can lower blood glucose, inhibit fat accumulation and ameliorate liver fibrosis.

Impact of Bitter Gourd (Momordica charantia) Hypoglycemic Formulation on Biochemical Parameters in Alloxan-induced Diabetic Albino Rats

Introduction: Diabetes mellitus is a widespread endocrine disorder that leads to chronic hyperglycemia, posing significant health challenges globally. Effective management of blood glucose levels remains a critical goal in diabetes treatment. Recent studies have highlighted the potential of natural products in diabetes management. Momordica charantia, commonly known as bitter gourd, has been traditionally used for its purported hypoglycemic effects. This study aims to evaluate the efficacy of a methanolic extract of Momordica charantia in reducing blood glucose levels in an animal model of diabetes and compare its effectiveness to a standard antidiabetic medication, Glizid-M. Materials and Methods: The study utilized alloxan-induced diabetic albino rats to assess the hypoglycemic effects of the methanolic extract of Momordica charantia. Diabetic rats were divided into groups and administered varying doses of the extract: 150 mg/kg, 300 mg/kg, and 600 mg/kg. A control group received Glizid-M, and a baseline group received no treatment. Blood glucose levels were monitored at regular intervals to evaluate the efficacy of the extract in managing hyperglycemia. Results and Discussion: The administration of the methanolic extract of Momordica charantia resulted in a dose-dependent reduction in blood glucose levels. Among the tested dosages, the 600 mg/kg dose demonstrated a statistically significant decrease in blood glucose compared to the lower doses of 150 mg/kg and 300 mg/kg. The 600 mg/kg dosage showed comparable efficacy to the standard antidiabetic drug, Glizid-M, indicating a strong hypoglycemic effect. The results of this study suggest that Momordica charantia has a potent hypoglycemic effect, with its efficacy increasing with dosage. The significant reduction in blood glucose levels at the highest dosage implies that the extract may influence glucose metabolism effectively. The dose-dependent response highlights the importance of optimizing dosage for maximum therapeutic benefit. Comparison with Glizid-M further supports the potential of Momordica charantia as a viable alternative or complementary therapy in diabetes management. Conclusion: This study provides scientific validation for the use of Momordica charantia methanolic extract as a therapeutic agent for diabetes management. The observed dose-dependent reduction in blood glucose levels suggests its potential as an effective natural remedy for controlling hyperglycemia. Further research is warranted to explore the underlying mechanisms and long-term efficacy of this extract in diabetes treatment.

Continuous glucose monitoring using machine learning models and IoT device data: A meta-analysis.

Machine learning offers diverse options for effectively managing blood glucose levels in diabetes patients. Selecting the right ML algorithm is critical given the array of available choices. Integrating data from IoT devices presents promising opportunities to enhance real-time blood glucose management models. This meta-analysis aims to evaluate the effectiveness of machine learning models utilizing IoT device data for predicting blood glucose levels. We systematically searched electronic databases for studies published between 2019 and 2023. We excluded studies lacking ML model derivation or performance metrics. The Quality Assessment of Diagnostic Accuracy Studies tool assessed study quality. Our primary outcomes compared ML models for BG level prediction across different prediction horizons (PHs). We analyzed ten eligible studies across prediction horizons of 15, 30, 45, and 60 minutes. ML models exhibited mean absolute RMSE values of 15.02 (SD 1.45), 21.488 (SD 2.92), 30.094 (SD 3.245), and 35.89 (SD 6.4) mg/dL, respectively. Random Forest demonstrated superior performance across these PHs. We observed significant heterogeneity across all subgroups, indicating diverse sources of variability. As the PH lengthened, the RMSE for blood glucose prediction by the ML model increased, with Random Forest showing the highest relative performance among the ML models.

Comparison of Glucose and Immunoglobulin a Levels in Serum and Saliva of Patients with Type 1 and Type 2 Diabetes

Introduction: The monitoring and management of blood glucose levels are of significant importance in individuals diagnosed with diabetes mellitus. Accordingly, the objective of this study was to examine the potential of a non-invasive approach for the diagnosis and management of diabetes, through the measurement of glucose concentration and salivary IgA, and a comparison with fasting glucose and serum IgA levels in individuals with type 1 and 2 diabetes, in relation to a control group of healthy individuals. Methods: This case-control study was conducted on 76 individuals with diabetes (31 with type 1 diabetes and 45 with type 2 diabetes) and 24 healthy individuals. After obtaining the code of ethics and informed consent, serum and salivary IgA levels as well as fasting glucose, were measured for each participant. The data were analyzed using SPSS version 16 statistical software and the Spearman, Kruskal-Wallis, and Mann-Whitney tests. Results: The results showed a significant difference among the three groups (type 1 diabetes, type 2 diabetes, and healthy group) based on Fasting Blood Glucose, Hemoglobin A1c, Immunoglobulin A, salivary sugar, and salivary IgA (p&lt;0.001). Additionally, in the case group, parameters such as FBS, HbA1c, and salivary IgA showed a significant correlation with salivary sugar. Conversely, in the control group, only the salivary sugar level demonstrated a significant relationship with serum glucose level. The study's findings indicated that serum and salivary IgA levels were lower and higher, respectively, in the control subjects compared to the diabetic group (p&lt;0.001). Conclusion: In healthy individuals, salivary sugar can serve as an indicator to determine fasting blood sugar levels. In diabetic patients, salivary sugar can predict of FBS, HbA1c, and salivary IgA levels.

Sports and diabetes - limitations resulting from the disease in people engaging in sports

Diabetes mellitus is a chronic condition that significantly impacts various aspects of daily life, including physical activity and sports participation. This article explores the limitations imposed by diabetes on individuals engaged in sports, examining both type 1 and type 2 diabetes. It discusses how the disease affects physical performance, endurance, and recovery, and highlights the need for careful management of blood glucose levels before, during, and after exercise. The potential risks of hypoglycemia and complications like diabetic neuropathy are addressed, alongside strategies for mitigating these risks through personalized exercise regimens, dietary adjustments, and continuous monitoring. Despite these challenges, the article emphasizes that with proper management and awareness, individuals with diabetes can safely engage in various forms of physical activity, often achieving high levels of performance. The discussion aims to provide athletes, coaches, and healthcare providers with insights into optimizing sports participation for diabetic individuals, promoting both safety and success in athletic endeavors.

Recent Findings on Exercise Therapy for Blood Glucose Management in Patients with Gestational Diabetes.

Inadequate management of blood glucose levels in gestational diabetes mellitus (GDM) poses risks for both pregnant women and the developing fetus. Attaining appropriate blood glucose control is crucial to mitigate potential adverse outcomes. This study aimed to consolidate the latest guidelines from representative professional societies, providing insights into exercise therapy for GDM patients and suggesting potential avenues for future research. The review was conducted with up-to-date exercise guidelines from prominent societies, such as the American College of Obstetricians and Gynecologists (ACOG), the Society of Obstetricians and Gynecologists of Canada (SOGC), the Canadian Society for Exercise Physiology (CSEP), the American College of Sports Medicine, the American Diabetes Association (ADA), and the Korean Diabetes Association. The ACOG and SOGC/CSEP recommend 150 min of low to moderate intensity exercise, 3-4 times a week, combining aerobic and resistance exercises. All guidelines advise against activities involving sudden directional changes, physical contact, a risk of falling, and exercises performed lying down. Despite cautions from the ADA and ACOG on blood glucose fluctuations during physical activity, the lack of specific methods and recommendations from other societies reveals a notable gap in evidence-based guidelines for GDM. For effective and safe blood glucose management in GDM patients, further research should be conducted on the exercise-related precautions outlined for GDM patients. Establishing ample evidence would facilitate the development of customized exercise guidelines for GDM patients.

Quercetin slow-release system delays starch digestion via inhibiting transporters and enzymes

This study investigates the potential of a quercetin-based emulsion system to moderate starch digestion and manage blood glucose levels, addressing the lack of in vivo research. By enhancing quercetin bioaccessibility and targeting release in the small intestine, the emulsion system demonstrates significant inhibition of starch digestion and glucose spikes through both in vitro and in vivo experiments. The system inhibits α-amylase and α-glucosidase via competitive and mixed inhibition mechanisms, primarily involving hydrogen bonds and van der Waals forces, leading to static fluorescence quenching. Additionally, this system downregulates the protein expression and gene transcription of SGLT1 and GLUT2. These findings offer a novel approach to sustaining glucose equilibrium, providing a valuable foundation for further application of quercetin emulsion in food science.

Medical database analysis of the association between kidney function and achievement of glycemic control in older Japanese adults with type 2 diabetes who started with oral antidiabetic drugs.

Despite the emergence of new drugs with novel mechanisms of action, treatment options for older people and those with chronic kidney disease are still limited. Using a medical database compiled from Diagnostic Procedure Combination hospitals, we retrospectively analyzed treatment status, glycemic control and kidney function over 3 years after the first oral antidiabetic drugs in Japanese adults with type 2 diabetes who were aged ≥65 years. Among 5,434 study participants, 3,246 (59.7%) were men, the median age was 72.0 years, the baseline median hemoglobin A1c was 7.1% and the baseline median estimated glomerular filtration rate was 66.6 mL/min/1.73 m2. Treatment was intensified in 40.0% of people during the 3-year observation period, and the median time to the first treatment intensification was 198 days. Insulin was the most commonly used agent for treatment intensification (36.9%, 802/2,175). Hemoglobin A1c of <7.0% was achieved in 3,571 (65.7%) at 360 ± 90 days. Multivariable logistic regression analysis found that baseline age, hemoglobin A1c and estimated glomerular filtration rate were negatively associated with achieving hemoglobin A1c of <7.0% at 360 ± 90 days. In older Japanese adults with type 2 diabetes, those with a lower estimated glomerular filtration rate were more likely to achieve hemoglobin A1c of <7.0%. To safely manage blood glucose levels in older adults with chronic kidney disease, physicians should remain vigilant about the risk of iatrogenic hypoglycemia.

Stress Levels, Hyperglycemia, and Long Suffering from Diabetes Relationship with Diabetic Neuropathy Pain

Diabetes mellitus often causes death in sufferers, making prevention and treatment are necessary to address its various chronic issues. This study examines the relationship between stress levels, hyperglycemia, and long suffering from diabetes with diabetic neuropathy pain. It employs a correlational analysis using a cross sectional design conducted between August 2023 and 2024. The population was all diabetes mellitus patients in the UPTD area of the North Gunungsitoli Health Centerw with a sample of 103 individuals selected through proportional stratified random sampling. The research instrument was a questionnaire covering each independent and dependent variable: stress level (15 items), hyperglycemia (15 items), long-term diabetes (10 items), and neuropathy pain (10 items). Data collection included both primary and secondary data from respondents and the Gunungsitoli City Office. The data were analyzed using univariate, bivariate, and multivariate tests, with bivariate analysis conducted using spearman rank correlation and multivariate analysis using logistic regression. The results indicated a positive and significant relationship between independent and the dependent variable, with values for stress levels (p=0.000), hyperglycemia (p=0.003), and long suffering from diabetes (p=0.002). Thus, it can be concluded that the knowledge and awareness of people with diabetes mellitus are crucial for their ability to engage in healthy physical activity, regulate their diet, consistently take medication, and manage blood glucose levels.

The Evaluation of the protective roles of canagliflozin and zinc sulphate on body weight and hepatic histology in diabetic dyslipidemia

The significant increase in diabetes prevalence in the past decade has placed a considerable strain on the global healthcare system, especially in developing nations such as Pakistan. Although current therapy options effectively manage blood glucose levels, their accompanying adverse effects can hinder patient adherence. This study investigates the therapeutic properties of Canagliflozin, a SGLT-2 inhibitor, recognized for its tolerance and supplementary advantages on body weight and blood pressure, when used in combination with Zinc Sulphate. Zinc is acknowledged for its function in the regulation of hyperglycemia and dyslipidemia. The study involved the use of a type-2 diabetic rat model, induced by a high-fat diet and streptozotocin to examine the separate and combined impacts of Canagliflozin and Zinc Sulphate on the liver's histology. A total of forty-eight male Sprague-Dawley rats were separated into six groups and the treatments were delivered for eight weeks. Body weights were observed and histological evaluations of the liver were performed with the NASH-CRN scoring system. The findings exhibited a notable decrease in body weight among the diabetic-induced groups in comparison to the normal control. The combined utilization of Canagliflozin and Zinc Sulphate showed a heightened efficacy in managing diabetes related weight loss and steatosis of liver in the rat model having type-2 diabetes. This indicates a possible combined treatment strategy that should be further investigated to enhance the management of hepatic steatosis in individuals with diabetes. The study also proposes the potential for using a reduced dosage of Canagliflozin in combination with Zinc, so limiting adverse effects.

Managing blood glucose levels with a hybrid closed-loop system in a patient with type 1 diabetes mellitus on enteral nutrition: A case report

The achievement of glycemic management is challenging in patients with diabetes on enteral nutrition, limited literature exists on hybrid closed-loop systems’ efficacy in such a situation. We described the case of a patient with type 1 diabetes treated by advanced hybrid closed loop on enteral nutrition with satisfactory glycemic management.

Fluorinated indeno-quinoxaline bearing thiazole moieties as hypoglycaemic agents targeting α-amylase, and α-glucosidase: synthesis, molecular docking, and ADMET studies

Inhibition of α-glucosidase and α-amylase are key tactics for managing blood glucose levels. Currently, stronger, and more accessible inhibitors are needed to treat diabetes. Indeno[1,2-b] quinoxalines-carrying thiazole hybrids 1–17 were created and described using NMR. All analogues were tested for hypoglycaemic effect against STZ-induced diabetes in mice. Compounds 4, 6, 8, and 16 were the most potent among the synthesised analogues. These hybrids were examined for their effects on plasma insulin, urea, creatinine, GSH, MDA, ALT, AST, and total cholesterol. Moreover, these compounds were tested against α-glucosidase and α-amylase enzymes in vitro. The four hybrids 4, 6, 8, and 16 represented moderate to potent activity with IC50 values 0.982 ± 0.04, to 10.19 ± 0.21 for α-glucosidase inhibition and 17.58 ± 0.74 to 121.6 ± 5.14 μM for α-amylase inhibition when compared to the standard medication acarbose with IC50=0.316 ± 0.02 μM for α-glucosidase inhibition and 31.56 ± 1.33 μM for α-amylase inhibition. Docking studies as well as in silico ADMT were done.

Low molecular weight chitosan (∼20 kDa) exhibits in vivo anti-hyperglycemic effects through AKT/PI3K/FOXO pathway

Diabetes, a metabolic syndrome, is a leading global cause of morbidity and mortality. Dietary polysaccharide intervention besides medication, helps in diabetes through managing blood glucose levels. The present study elucidates the anti-hyperglycemic mechanism of water-soluble LMWC (∼20 kDa), the chitosan derivative, in type-1 diabetic (T1DM) male Wistar rats induced by streptozotocin (STZ, 36 mg/kg b.w.). LMWC1 (100 mg/kg b.w.) and LMWC2 (250 mg/kg b.w.) were administered orally on alternative days for 4 weeks. LMWC lowered fasting blood glucose levels and improved symptoms like polyphagia, polydipsia, polyuria, and serum insulin levels in a dose-dependent manner. It also ameliorated hyperglycemia & dyslipidemia by mitigating the levels of pro-inflammatory factors and oxidative stress levels in the pancreas and liver. Additionally, LMWC increased the activity of key proteins involved in insulin signaling in these organs through the AKT/PI3K/FOXO pathway, enhancing insulin secretion and improving glucose metabolism in T1DM rats. This contributed to improved hepatic glycogen synthesis and suppression of gluconeogenesis in T1DM rats. In summary, LMWC could be an effective antidiabetic supplement, offering insights into dietary treatment for diabetes management.

Smart Contact Lens for Colorimetric Visualization of Glucose Levels in the Body Fluid.

Frequent blood glucose monitoring is a crucial routine for diabetic patients. Traditional invasive methods can cause discomfort and pain and even pose a risk of infection. As a result, researchers have been exploring noninvasive techniques. However, a limited number of products have been developed for the market due to their high cost. In this study, we developed a low-cost, highly accessible, and noninvasive contact lens-based glucose monitoring system. We functionalized the surface of the contact lens with boronic acid, which has a strong but reversible binding affinity to glucose. To achieve facile conjugation of boronic acid, we utilized a functional coating layer called poly(tannic acid). The functionalized contact lens binds to glucose in body fluids (e.g., tear) and releases it when soaked in an enzymatic cocktail, allowing for the glucose level to be quantified through a colorimetric assay. Importantly, the transparency and oxygen permeability of the contact lens, which are crucial for practical use, were maintained after functionalization, and the lenses showed high biocompatibility. Based on the analysis of colorimetric data generated by the smartphone application and ultraviolet-visible (UV-vis) spectra, we believe that this contact lens has a high potential to be used as a smart diagnostic tool for monitoring and managing blood glucose levels.

Novel Approaches to Control Diabetes.

Diabetes is a chronic, long-term, incurable, but controllable condition. Diabetes mellitus (DM) is a group of metabolic disorders characterized by hyperglycemia that results from defects in insulin secretion, insulin action, or both. People who have diabetes often experience a variety of symptoms, including blurry vision, excessive thirst, fatigue, frequent urination, hunger, and weight loss. This review article includes a discussion on diabetes types, symptoms, diagnostic tests, and various therapies for treating, controlling, and managing blood glucose levels, with a focus on its most recent innovation of therapies and medications. Diabetes management will also be reviewed, along with clinical pharmacodynamics, bioavailability, advantages, and complications of combined drugs/medications.